Acuity Reports Positive Phase II Data for AMD Drug; Eyes Phase III in Mid-'07, NDA in Mid-'09

The company said that bevasiranib was safe and well-tolerated in the uncontrolled trial, demonstrating dose-dependent decreases of the lesions that characterize wet AMD.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.